June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Complement C5a induced Epithelium to Mesenchymal Transition (EMT) in retinal pigment epithelial cells
Author Affiliations & Notes
  • Maria Llorian-Salvador
    Welcome-Wolfson Institute for Experimental Medicin, Belfast, NORTHERN IRELAND, United Kingdom
  • Eimear Margaret Byrne
    Welcome-Wolfson Institute for Experimental Medicin, Belfast, NORTHERN IRELAND, United Kingdom
  • Karis Little
    Welcome-Wolfson Institute for Experimental Medicin, Belfast, NORTHERN IRELAND, United Kingdom
  • Mei Chen
    Welcome-Wolfson Institute for Experimental Medicin, Belfast, NORTHERN IRELAND, United Kingdom
  • Heping Xu
    Welcome-Wolfson Institute for Experimental Medicin, Belfast, NORTHERN IRELAND, United Kingdom
  • Footnotes
    Commercial Relationships   Maria Llorian-Salvador, None; Eimear Byrne, None; Karis Little, None; Mei Chen, None; Heping Xu, None
  • Footnotes
    Support  Fight for Sight (1574/1575).
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1116. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maria Llorian-Salvador, Eimear Margaret Byrne, Karis Little, Mei Chen, Heping Xu; Complement C5a induced Epithelium to Mesenchymal Transition (EMT) in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1116.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Subretinal fibrosis affects around one third of patients with neovascular age related macular degeneration (nAMD) and can cause severe vision loss. The underlying mechanism remains poorly defined. We previously reported higher plasma levels of C3a and C5a in nAMD patients with macular fibrosis. The aim of this study was to understand if C3a or C5a can induce Epithelial-Mesenchymal Transition (EMT) in retinal pigment epithelial (RPE) cells.

Methods : Subretinal fibrosis was induced in mice using a protocol described by Little et al. The presence of C5aR in the fibrotic lesion was examined by immunohistochemistry. Primary murine RPE cells were then treated with recombinant C3a or C5a (10-50 ng/ml) for different durations. Mouse recombinant TGF-β2 (10ng/ml) was used as a positive control for induction of EMT in RPE cells. Expression of epithelial and mesenchymal markers, (vimentin, fibronectin, α-SMA, Slug, and epithelial E-Cadherin) as well as the ERK/AKT and pSMAD2/3 pathways were determined by Western Blot and immunocytochemistry. Collagen contraction and wound healing were used as functional readouts of EMT, and subsequent cytokine and growth factor production and secretion was determine by ELISA and Western Blot

Results : C5aR was found to be expressed in subretinal fibrotic lesions that were characterized by fibronectin and collagen I positivity. In primary RPE cultures, TGF-β2 treatment (10ng/mL) upregulated the expression of C5aR and increased release of C5a. C5a treatment (96h) increased mesenchymal markers such as fibronectin, α-SMA, vimentin or Slug, and decreased the epithelial marker E-Cadherin. Functional evidence for the role of C5a in EMT was attained when primary RPE treated with C5a displayed increased contractility and migration following treatment.
Interestingly, C5a treatment also increased the production of IL-6 and VEGF, which are known pro-fibrotic mediators. Western Blot revealed that C5a-induced EMT is mediated by Smad2/3 and ERK1/2 signaling pathway activation. C5a-mediated EMT was completely prevented when C5aR was inhibited concomitantly with C5a treatment.

Conclusions : Our results show that the C5a/C5aR pathway may contribute to subretinal fibrosis through induction of EMT in RPE cells. Targeting this pathway may be a novel approach for the management of macular fibrosis.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×